| 1641 |
CABOZAN 20 MG |
CABOZANTINIB 20 MG |
CAPSULE |
BOTTLE |
FOR TREATMENT OF PATIENTS WITH PROGRESSIVE, METASTATIC MEDULLARY THYROID CANCER, RENAL CELL CARCINOMA AND HEPATOCELLULAR CARCINOMA. |
NULL |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS |
CERTIFICATE RELEASED |
03 L 0957/23 |
31-MAR-2025 |
30-MAR-2030 |
View |
| 1642 |
CAPANIB |
CAPMATINIB 200 MG |
TABLET |
BOTTLE |
Used for the treatment of adult patients with metastatic, non-small cell lung cancer (NSCLC) whose tumors have tested positive for a mutation that leads to MET exon 14 skipping |
NULL |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS |
CERTIFICATE RELEASED |
11 L 0934/22 |
06-DEC-2022 |
05-DEC-2025 |
View |
| 1643 |
CAVIR - 0.5 |
ENTECAVIR 0.5 MG |
TABLET |
BOTTLE |
for the treatment of chronic hepatitis B virus (HBV) |
NULL |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS |
CERTIFICATE RELEASED |
11 L 0941/22 |
06-DEC-2022 |
05-DEC-2025 |
View |
| 1644 |
CLOPIDOGREL |
CLOPIDOGREL 75 MG |
FILM COATED TABLET |
BLISTERPACK |
FOR SECONDARY PREVENTION OF ARTHEROSCLEROSIS AND THROMBOSIS EVENT |
NULL |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS |
CERTIFICATE RELEASED |
07 L 1152/24 |
07-AUG-2024 |
06-AUG-2027 |
View |
| 1645 |
ELAPRIL-20 |
ENALAPRIL MALEATE 20 MG |
TABLET |
BLISTERPACK |
PRIMARY HYPERTENSION, RENOVASCULAR HYPERTENSION |
NULL |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS |
CERTIFICATE RELEASED |
07 L 1154/24 |
07-AUG-2024 |
06-AUG-2027 |
View |
| 1646 |
ELAPRIL-5 |
ENALAPRIL MALEATE 5 MG |
TABLET |
BLISTERPACK |
PRIMARY HYPERTENSION, RENOVASCULAR HYPERTENSION |
NULL |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS |
CERTIFICATE RELEASED |
07 L 1135/24 |
12-JUL-2024 |
2027-07-11 |
View |
| 1647 |
ESOMIRAZO |
ESOMEPRAZOLE 20 MG |
CAPSULE |
BLISTERPACK |
GASTROESOPHAGEAL REFLUX DISEASE: TREATMENT OF REFLUX ESOPHAGITIS, PATIENTS WITH GASTRIC ULCERS WHO REQUIRE CONTINUOUS NSAID TREATMENT |
NULL |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS |
CERTIFICATE RELEASED |
02 L 1060/24 |
20-FEB-2024 |
19-FEB-2027 |
View |
| 1648 |
ESOMIRAZO |
ESOMEPRAZOLE 40 MG |
CAPSULE |
BLISTERPACK |
GASTROESOPHAGEAL REFLUX DISEASE: TREATMENT OF REFLUX ESOPHAGITIS, PATIENTS WITH GASTRIC ULCERS WHO REQUIRE CONTINUOUS NSAID TREATMENT |
NULL |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS |
CERTIFICATE RELEASED |
02 L 1059/24 |
20-FEB-2024 |
19-FEB-2027 |
View |
| 1649 |
I-MECT 12 |
IVERMECTIN 12 MG |
TABLET |
BLISTERPACK |
TO TREAT STRONGYLOIDIASIS, ONCHOCERCIASIS, ASCARIASIS, TRICHURIASIS AND ENTEROBIASIS |
NULL |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS |
CERTIFICATE RELEASED |
10 L 0930/22 |
11-Nov-2022 |
10-Nov-2025 |
View |
| 1650 |
I-MECT 3 |
IVERMECTIN 3 MG |
TABLET |
BLISTERPACK |
TO TREAT STRONGYLOIDIASIS, ONCHOCERCIASIS, ASCARIASIS, TRICHURIASIS AND ENTEROBIASIS |
NULL |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS |
CERTIFICATE RELEASED |
10 L 0931/22 |
11-Nov-2022 |
10-Nov-2025 |
View |
